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Abstract
Objectives: Potassium iodide (KI) is a medication that has 
been used for decades in dermatology and it is mentioned 
as a treatment option in all major dermatology textbooks. 
Yet, there is little recent information on its efficacy. In our 
study, we wanted to retrospectively evaluate the therapy re-
sponse to KI in our patients. Methods: The hospital informa-
tion system was searched for patients treated with KI at the 
Department of Dermatology (University Hospital Zurich) in 
the last 20 years (January 1, 1998 to December 31, 2017). A 
total of 52 patients were found and, subsequently, 35 pa-
tients were included in our study. Results: KI was prescribed 
for the following skin conditions: erythema nodosum, dis-
seminated granuloma anulare, necrobiosis lipoidica, nodu-
lar vasculitis, cutaneous sarcoidosis, and granulomatous 
perioral dermatitis/ rosacea. The median duration of KI in-
take was 5 ± 7.7 weeks (range 1–26). The global assessment 
of efficacy by the treating physician showed an improve-
ment of disease in about a third of all patients. No response 
was seen in 14 patients and 9 even had a progression of 
disease. An adverse event was documented in 16 cases. 
Conclusions: Our findings show that an improvement was 
reached in only about a third of all cases. High response 
rates with only mild side effects (in 16 out of 35 patients) 
were observed. © 2018 S. Karger AG, Basel
Introduction
Potassium iodide (KI) is a medication that has been 
used for decades in dermatology [1]. Kl is a photosensi-
tive crystal composed of salt (76%) and potassium (23%) 
[2]. It was originally used to treat thyroid disorders and 
was then obtained from seaweed in ancient times. Its des-
ignated use encompassed diseases like psoriasis, eczema, 
tuberculosis, and syphilis [2, 3].
Nowadays, KI represents a treatment option in inflam-
matory, granulomatous, and infectious diseases, like ery-
thema nodosum [4], nodular vasculitis [4], subacute mi-
gratory panniculitis [5], granuloma anulare [6, 7], pyoder-
ma gangrenosum [8], granulomatosis with polyangiitis, 
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Behçet’s disease, Sweet’s syndrome [1, 9], cryptococcosis 
[10], and zygomycosis [11]. Most studies have been per-
formed on sporotrichosis [12–18]. KI has a fast effect on 
dermatosis. It is reported that remission occurs within 
days or weeks [19]. For inflammatory dermatosis, the rec-
ommended dosage is 300 mg three times daily [20].
Nondermatological indications include emphysema, 
cystic fibrosis, and cataract [2, 21–23]. It is controversial 
whether KI can be administered to patients with thyroid 
disease [1, 2, 19, 24, 25]. However, in case of a nuclear 
emergency, KI is used as a thyroid blocker [26]. Observed 
side effects include nausea, vomiting, and skin changes 
such as eczema and acneiform rashes [4]. An excess of 
iodine can cause thyrotoxicosis (Jod-Basedow effect) 
[20].
The absorption of iodine through the skin is poor, 
which makes it a commonly used topical disinfectant. 
When orally applied, KI is concentrated in the thyroid 
gland and excreted in urine, as well as feces. It has been 
proven to be teratogenic and should thus not be applied 
in pregnant women [2].
The precise mechanism of action has not been revealed 
[2]. However, it is assumed that its anti-inflammatory ef-
fects are partly exerted by the suppression of toxic oxy-
gen, inhibition of chemotaxis, as well as by halogenation 
reactions from myeloperoxidases [27–29]. There is no di-
rect antibacterial or antifungal activity [30]. 
Data on its efficacy are scarce, as only little interest ex-
ists from scientific centers and pharmaceutical compa-
nies. In fact, no randomized, placebo-controlled, or dou-
ble-blind studies on its efficacy have been conducted [2]. 
Nonetheless, for more than a century clinical researchers 
have described its efficacy in multiple diseases. In our 
study, we wanted to retrospectively evaluate the efficacy 
of KI in our patients.
Materials and Methods
For further details, see the online supplementary material (see 
www.karger.com/doi/10.1159/000494614 for all online suppl. ma-
terial) (Fig. 1).
Results
A total of 35 patients were included in our study (Table 
1): 11 patients were diagnosed with disseminated granu-
loma anulare, 9 with erythema nodosum, 7 suffered from 
necrobiosis lipoidica, and 3 patients had a cutaneous 
manifestation of sarcoidosis. The remaining patients suf-
fered from granulomatous perioral dermatitis or granu-
lomatous rosacea (n = 3) and 2 were diagnosed with nod-
ular vasculitis (Fig. 2; Table 2). In our cohort, there was 
no complete clearing: 12 out of 35 showed an improve-
ment as judged by the physician, no response was seen in 
14 patients, and 9 even had a progression of disease 
(Fig. 3a). From the 9 patients with erythema nodosum, 5 
showed an improvement, and the remaining 4 did not 
benefit from this treatment (Fig. 3b; Table 2). On the con-
trary, all 3 patients with granulomatous perioral derma-
titis or rosacea worsened during treatment. Similar re-
Search in the hospital information
system for patients being treated with
potassium iodide from 1998 to 2017
(n = 52)
Participants with one or more
follow-up visits (n = 38)
Excluded as no follow-up
data available (n = 14)
Oral use of potassium iodide
(n = 35)
Topical use of potassium
iodide (n = 3)
Fig. 1. Flowchart of Materials and Meth-
ods. Participant inclusion and exclusion.
Table 1. Overview of patients’ characteristics
Patients, n 35
Male 11
Female 24
Age, years 50±18 (18–79)
Data for age are presented as mean ± SD (range).
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sults were seen in cutaneous sarcoidosis. Disseminated 
granuloma anulare showed an improvement in 4/11, nec-
robiosis lipoidica in 2/7, and nodular vasculitis in 1/2. An 
adverse event was documented in 16 cases, namely hypo-
thyreosis, stomachache, palpitations, metallic sensation 
in the mouth, vertigo, obstipation, malaise, shivering, and 
hyperhidrosis. With the exception of hyperhidrosis and 
stomachache, which were Common Terminology Crite-
ria (CTC) grade 2, all side effects were CTC grade 1. The 
median duration of KI intake was 5 ± 7.7 weeks, but 
ranged from 1 to 26 weeks. On average, 900 ± 389 mg 
(range 130–1,800) KI was administered daily; 3/35 pa-
tients suffered from diabetes mellitus. KI was never used 
as a first-line treatment. However, in 20/35 it was a sec-
ond-line, in 7/35 a third-line, and in 4/35 a fourth-line 
treatment. It was never used as a fifth-line treatment and 
was used as a sixth-line treatment in 1 case. In almost all 
cases topical steroids were used as first-line treatments. 
Topical calcineurin inhibitors or systemic, immunomod-
ulating antibiotics, such as dapsone or tetracyclines, were 
also used (Table 3).
Discussion/Conclusion
KI has been used in dermatology for a long time [1, 4]. 
The reports of Schulz and Whiting [31], where 24/28 pa-
tients suffering from erythema nodosum as well as 16/17 
patients suffering from nodular vasculitis responded to 
therapy with KI, revived its use in modern clinics. The 
findings were confirmed by Horio et al. [4]. In fact, in 
some cases first signs of response were seen within 24 h, 
Disseminated
granuloma anulare
Necrobiosis
lipoidica
Nodular vasculitis
Sarcoidosis
Granulomatous
perioral dermatitis/
rosacea
Erythema nodosum
11
7
2
3
3
9
Fig. 2. Diseases treated with potassium iodide.
Table 2. Patients’ response to treatment according to disease
  Total Re-
mis-
sion
Im-
prove-
ment
No re-
sponse
Progres-
sion of 
disease
Erythema nodosum 9 0 5 3 1
Disseminated granuloma
anulare 11 0 4 5 2
Necrobiosis lipoidica 7 0 2 5 0
Nodular vasculitis 2 0 1 0 1
Cutaneous sarcoidosis 3 0 0 1 2
Granulomatous perioral
dermatitis/rosacea 3 0 0 0 3
Data are presented as number of patients.
Granulomatous perioral dermatitis/rosacea
Nodular vasculitis
Sarcoidosis
Necrobiosis lipoidica
Erythema nodosum
Disseminated granuloma
0 5
Patients, n
Pa
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nt
s, 
n
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0
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No
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■ No treatment response
■ Treatment response
Fig. 3. a Treatment response to potassium iodide. b Treatment response stratified according to disease.
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Table 3. Patients’ clinical characteristics
Age,
years
Sex Dosage (max) Duration, 
weeks
Disease Previous treatments LOT R I NR POD AE CTC 
grade
TOT DM
79 F 900 mg/d 4 disseminated 
granuloma 
anulare
TS, UVA1 3 x hypothy-reosis yes no
48 F 900 mg/d 3 erythema nodosum TS 2 x no   yes no
24 F 300 mg/d 9 necrobiosis 
lipoidica
TS 2 x no   yes no
69 F 900 mg/d 3 granulomatous
perioral dermatitis/
rosacea
tacrolimus, SS, oral 
tetracyclines, topical 
macrolides
5 x no   yes no
72 F 900 mg/d 3 erythema nodosum TS, SS x no   yes yes
54 M 900 mg/d 1 granulomatous
perioral dermatitis/
rosacea
topical pimecrolimus, oral 
tetracycline, oral 
nitroimidazole
4 x stomachache 1 yes no
68 M 1,500 mg/d 12 disseminated
granuloma 
anulare
TS, UVA1, intra-
lesional triamcinolon 
injections
4 x no   no no
50 M 900 mg/d 4 cutaneous 
sarcoidosis
TS (patient was under 
systemic tacrolimus, 
mycophenolat-mofetil)
2 x no   no no
45 F 900 mg/d 5 necrobiosis 
lipoidica
TS, topical pimecrolimus 3 x palpation 1 no no
55 F 900 mg/d 11 disseminated 
granuloma 
anulare
TS 2 x metallic 
sensation in 
mouth
1 yes no
63 F 600 mg/d 12 disseminated
granuloma 
anulare
TS, UVA1 3 x hypothy-reosis 1 yes no
18 F 900 mg/d 36 disseminated
granuloma 
anulare
TS 2 x no   no no
57 M 1,800 mg/d 9 disseminated
granuloma 
anulare
TS, dapson 2 x no   yes no
72 F 900 mg/d 3 erythema nodosum TS, SS 3 x no   yes no
29 F 900 mg/d 9 cutaneous 
sarcoidosis
TS 2 x no   yes no
45 F 1,800 mg/d 5 necrobiosis
lipoidica
TS, topical pimecrolimus 2 x palpation, 
hypothy-reosis
1 no no
57 F 900 mg/d 8 erythema
nodosum
TS, SS 3 x no   yes no
63 F 1,800 mg/d 6 disseminated 
granuloma 
anulare
TS 2 x no   yes no
54 F 900 mg/d 3 granulomatous
perioral dermatitis/
rosacea
TS, topical tacrolimus, 
oral tetracyclines
4 x stomachache 2 yes no
38 M 600 mg/d 12 erythema nodosum TS 2 x no   no no
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leading to high expectations of this treatment option [4, 
20]. 
Unfortunately, our cohort yielded quite different re-
sults. Several factors could account for that.  The study 
design of Schulz and Whiting [31] was prospective, while 
we performed a retrospective analysis. Also, the patient 
selection shows differences. Both studies included several 
patients with erythema nodosum, but our study also 
yields data on other diseases like necrobiosis lipoidica, 
granulomatous perioral dermatitis/rosacea, and cutane-
ous sarcoidosis. In the study of our colleagues, 17 patients 
were treated for nodular vasculitis, whereas our cohort 
only encompassed 2 such patients.
The probability of pharmacological differences seems 
to be rather low. As in the study of Schulz and Whiting, 
our patients received KI either in tablet form or as drops. 
The dose of KI in our patients was on average even high-
er than that in the cohort of Schulz and Whiting.
Age,
years
Sex Dosage (max) Duration, 
weeks
Disease Previous treatments LOT R I NR POD AE CTC 
grade
TOT DM
19 F 900 mg/d 4 necrobiosis 
lipoidica
TS, topical pimecrolimus 3 x no   yes yes
50 M 900 mg/d 16 erythema nodosum TS 2 x no   no no
73 F 300 mg/d 4 erythema
nodosum
TS 2 x vertigo 1 no no
59 F 900 mg/d 4 disseminated
granuloma 
anulare
TS 2 x no   yes no
35 M 900 mg/d 4 erythema
nodosum
TS 2 x no   no no
72 F 900 mg/d 4 cutaneous 
sarcoidosis
TS 2 x obstipation 1 yes no
36 F 900 mg/d 4 erythema
nodosum
TS 2 x no   no no
26 F 900 mg/d 4 nodular 
vasculitis
TS 2 x hypothy-reosis no no
77 F 600 mg/d 24 disseminated
granuloma 
anulare
TS 2 x no 1 yes no
36 F 900 mg/d 5 necrobiosis 
lipoidica
TS 2 x no   yes yes
55 M 900 mg/d 24 disseminated
granuloma 
anulare
TS 2 x malaise   yes no
58 M 1,800 mg/d 6 disseminated
granuloma 
anulare
TS, SS 3 x no   yes no
22 M 900 mg/d 1 necrobiosis 
lipoidica
TS, dapson, SS, MTX, 
UVA
6 x no   yes no
35 M 900 mg/d 20 necrobiosis 
lipoidica
TS, SS, pentoxifylline, 
topical pimecrolimus
4 x hyperhi-
drosis
2 no no
51 F 130 mg/d 2 nodular 
vasculitis
TS, topical pimecrolimus 3 x shivering 1 yes no
LOT, line of treatment; R, remission; I, improvement; NR, no response; POD, progression of disease; AE, adverse events; TOT, termination of therapy 
at or before next consultation; DM, diabetes mellitus; d, day; TS, topical steroids; UVA, UV-A light therapy; SS, systemic steroids.
Table 3 (continued)
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Our patients also received NSAIDs and topical ste-
roids during the KI therapy in almost all cases, which 
would lead to the conclusion that our results would be 
superior to those previously published. In both studies 
(silent) malcompliance is a bias that cannot be ruled out, 
but we discovered only 5 cases of documented malcom-
pliance in our cohort. 
It has to be mentioned that for diagnoses like erythema 
nodosum and disseminated granuloma anulare (here KI 
showed the best treatment response in our study), we see 
a high rate of spontaneous remission in daily practice. 
Unfortunately, we cannot confirm our findings, as no 
data on the rates of spontaneous remission for those dis-
eases exist. 
As many scientists prefer to publish only positive data, 
publication bias may also be an explanation. Maybe other 
groups came to similar results as we did but abstained 
from publishing them. The small sample sizes in both 
studies may be a contributing bias. 
Since there are no randomized, double-blind studies, 
and most of the existing studies have low numbers, it is 
difficult to make a final judgement with the evidence we 
have. Out of all dermatosis treated with KI, most of the 
existing data is on sporotrichosis [13–18], and the largest 
study included 645 patients [32]. Nonetheless, a Co-
chrane review found that even in this case, there is not 
enough (high-quality) evidence to come to a final conclu-
sion regarding its efficacy [33]. 
In summary, in our opinion KI should not be first-line 
treatment. Depending on the disease, other therapeutic 
options should be sought first. Only in case of therapy 
refractory diseases and nonresponse to other first- and 
second-line therapeutics should KI be considered. Nota-
bly, in our cohort KI worked best in diseases with a high 
rate of spontaneous remissions, thus a double-blind study 
would be helpful to evaluate its efficacy.
It is surprising that our data differed from the previ-
ously published results. Nonetheless, we find it of high 
value to publish negative results to avoid a possible mis-
conception by clinicians. In fact, we fear that due to pub-
lication bias many patients worldwide undergo treatment 
with KI, whose potential efficacy is, we believe, overesti-
mated. In our view, this topic is of importance, as KI is 
mentioned as a treatment option in all well-known der-
matology books, such as Rook’s Textbook of Dermatology, 
Fitzpatrick’s Dermatology in General Medicine, and Der-
matology by Jean Bolognia. 
We encourage other groups to analyze their treatment 
success with KI, but especially prospective, randomized, 
double-blind studies are needed to confirm the described 
effects of KI on dermatological diseases. 
Key Message
Even though therapy with potassium iodide is mentioned in 
every major dermatology textbook, our cohort did not show high 
response rates such as those published previously.
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col was approved by the research institute’s committee on human 
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